88 related articles for article (PubMed ID: 3493744)
1. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma.
Neely SM; Mehlmauer M; Feinstein DI
Arch Intern Med; 1987 Mar; 147(3):529-31. PubMed ID: 3493744
[TBL] [Abstract][Full Text] [Related]
2. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
Kessler JF; Jones SE; Levine N; Lynch PJ; Booth AR; Meyskens FL
Arch Dermatol; 1987 Feb; 123(2):201-4. PubMed ID: 2949706
[TBL] [Abstract][Full Text] [Related]
3. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
[TBL] [Abstract][Full Text] [Related]
4. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
[TBL] [Abstract][Full Text] [Related]
5. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
[TBL] [Abstract][Full Text] [Related]
6. Isotretinoin treatment of rosacea.
Turjanmaa K; Reunala T
Acta Derm Venereol; 1987; 67(1):89-91. PubMed ID: 2436425
[TBL] [Abstract][Full Text] [Related]
7. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
[TBL] [Abstract][Full Text] [Related]
9. T-cell receptor-gamma gene analysis in evolving to advancing cutaneous T-cell lymphoma.
Foo CC; Tang MB; Chong TK; Sun YJ; Tan SH
Australas J Dermatol; 2007 Aug; 48(3):156-60. PubMed ID: 17680965
[TBL] [Abstract][Full Text] [Related]
10. Isotretinoin: new therapy for severe acne.
Perry MD; McEvoy GK
Clin Pharm; 1983; 2(1):12-9. PubMed ID: 6192964
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and therapy of cutaneous T-cell lymphomas].
Le T; Pierard GE; Pierard-Franchimont C; de la Brassinne M; Lapière CM
Dermatologica; 1984; 169(2):60-5. PubMed ID: 6332749
[TBL] [Abstract][Full Text] [Related]
12. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas.
Neelis KJ; Schimmel EC; Vermeer MH; Senff NJ; Willemze R; Noordijk EM
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):154-8. PubMed ID: 18834672
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus.
Newton RC; Jorizzo JL; Solomon AR; Sanchez RL; Daniels JC; Bell JD; Cavallo T
Arch Dermatol; 1986 Feb; 122(2):170-6. PubMed ID: 3511858
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
15. Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides.
Copur MS; Deshpande A; Mleczko K; Norvell M; Hrnicek GJ; Woodward S; Frankforter S; Mandolfo N; Fu K; Chan WC
Croat Med J; 2005 Jun; 46(3):458-62. PubMed ID: 15861527
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG; Wilson LD; Braverman IM; Feldman AM; Kacinski BM
Arch Dermatol; 1995 Apr; 131(4):432-5. PubMed ID: 7726585
[TBL] [Abstract][Full Text] [Related]
17. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents.
Dolan ME; McRae BL; Ferries-Rowe E; Belanich M; van Seventer GA; Guitart J; Pezen D; Kuzel TM; Yarosh DB
Clin Cancer Res; 1999 Aug; 5(8):2059-64. PubMed ID: 10473086
[TBL] [Abstract][Full Text] [Related]
18. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
19. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma.
Gerami P; Wickless SC; Rosen S; Kuzel TM; Ciurea A; Havey J; Guitart J
J Am Acad Dermatol; 2008 Aug; 59(2):245-54. PubMed ID: 18486274
[TBL] [Abstract][Full Text] [Related]
20. Mycosis fungoides associated with B-cell malignancies.
Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
